Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31714 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Seth E Karol und 29 weiteren Autor:innen. Beteiligte Einrichtung: St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background Venetoclax is a potent, oral BCL‐2 inhibitor approved as combination therapy for the treatment of adults with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. This study evaluated the safety and preliminary efficacy of venetoclax alone or combined with chemotherapy in paediatric and adolescent/young adult patients with relapsed/refractory AML. Procedure In this phase 1, open‐label, two‐part, multicentre study, paediatric and adolescent/young adult patients (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Royal Children's Hospital, Melbourne, VIC, Australia.
- Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands, and Department of Pediatric Oncology, Erasmus MC Sophia Children's Hospital, Rotterdam, the Netherlands.
- Hôpital Universitaire Robert Debré (APHP) and Université Paris Cité, Paris, France.
- CHU Sainte-Justine, Montréal, QC, Canada.
- Seattle Children's Hospital, Cancer and Blood Disorders Center, Seattle, Washington, USA.
ORCID-Profile: Seth E Karol, Todd M Cooper, Margaret E Macy, Daniel A Morgenstern, Andrew E Place
Zitieren
APA
Karol, S. E., Khaw, S. L., Zwaan, C. M., Baruchel, A., Bittencourt, H., Cooper, T. M., Flotho, C., Fraser, C., Forlenza, C. J., Goldsmith, K. C., Macy, M. E., Morgenstern, D. A., O'Brien, M. M., Petit, A., Ziegler, D. S., Reinhardt, D., Opferman, J. T., Rubnitz, J. E., Onishi, M., …, & Place, A. E. (2025). Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31714
Vancouver
Karol SE, Khaw SL, Zwaan CM, Baruchel A, Bittencourt H, Cooper TM, et al. Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31714
BibTeX
@article{Karol2025,
author = {Karol, Seth E and Khaw, Seong L and Zwaan, C Michel and Baruchel, Andre and Bittencourt, Henrique and Cooper, Todd M and Flotho, Christian and Fraser, Christopher and Forlenza, Christopher J and Goldsmith, Kelly C and Macy, Margaret E and Morgenstern, Daniel A and O'Brien, Maureen M and Petit, Arnaud and Ziegler, David S and Reinhardt, Dirk and Opferman, Joseph T and Rubnitz, Jeffrey E and Onishi, Maika and Dunshee, Diana R and Dunbar, Fengjiao and Vishwamitra, Deeksha and Ross, Jeremy A and Chen, Xin and Unnebrink, Kristina and Kammerlander, Maja and Salem, Ahmed Hamed and Palenski, Tammy L and Sunkersett, Gauri and Place, Andrew E},
title = {Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31714}
}
EUVIMED